<SEC-DOCUMENT>0001178913-15-003710.txt : 20151214
<SEC-HEADER>0001178913-15-003710.hdr.sgml : 20151214
<ACCEPTANCE-DATETIME>20151214121248
ACCESSION NUMBER:		0001178913-15-003710
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151214
FILED AS OF DATE:		20151214
DATE AS OF CHANGE:		20151214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36848
		FILM NUMBER:		151285197

	BUSINESS ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1517725.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1517725.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt">UNITED STATES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, DC 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">PURSUANT </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">TO </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">RULE 13a-16 OR 15d-16 </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">UNDER</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For&#160;December 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Commission File No. 001-</font><font style="DISPLAY: inline">36848</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Check-Cap Ltd. </font>
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Check-Cap Building</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Abba Hushi Avenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O. Box 1271</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Isfiya, 30090</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Mount Carmel, Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F <font style="DISPLAY: inline">or</font> Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Form 40-F<font style="DISPLAY: inline; FONT-SIZE: 10pt"> <font style="DISPLAY: inline;" face="Wingdings">o</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark <font style="DISPLAY: inline">if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Indicate by check mark </font>whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12<font style="DISPLAY: inline">g</font>3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">o</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 180pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):<font style="DISPLAY: inline"> 82</font>-<font style="DISPLAY: inline">___</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Post-Effective Amendment No. 1 to the Form S-8 Registration Statement File No. 333-203384.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 14, 2015, Check-Cap Ltd. (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;) issued a press release announcing that data related to its clinical studies have been published in <font style="FONT-STYLE: italic; DISPLAY: inline">Gut</font>, an official peer-reviewed journal of the British Society of Gastroenterology.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Press Release, dated December 14, 2015.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the <font style="DISPLAY: inline">requirements</font> of the&#160;<font style="DISPLAY: inline">Securities</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Exchange Act of 1934, the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline">registrant</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Check-Cap Ltd.</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Lior Torem</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name: Lior Torem</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title: Chief Financial Officer</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated: December 14, 2015</font></div>

<div align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: zk global-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right">
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 99.1</font></div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="img.jpg" alt=""></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Check-Cap Announces the Publication of Preliminary Clinical Data on its </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Preparation-Free Colon Screening Capsule in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">Gut</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ISFIYA, Israel, December 14, 2015 - Check-Cap Ltd. (the &#8220;Company&#8221; or &#8220;Check-Cap&#8221;) (NASDAQ:&#160;&#160;CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that data related to its clinical studies have been published in <font style="FONT-STYLE: italic; DISPLAY: inline">Gut</font>, an official peer-reviewed journal of the British Society of Gastroenterology.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The article, entitled &#8220;A Novel Prepless X-ray Imaging Capsule for Colon Cancer Screening,&#8221; includes safety and motility data collected in Europe and Israel on passage of the capsule through the GI tract, as well as a preliminary analysis of the first participants evaluated in the Company&#8217;s ongoing multi-center clinical feasibility study, <font style="DISPLAY: inline; FONT-SIZE: 10pt">which aims to establish the safety, functionality and preliminary efficacy of the Check-Cap system.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The importance of routine colorectal cancer screening is well understood. Colorectal cancer, or CRC, develops slowly and is therefore highly preventable. However, there are logistical and patient-related barriers that hamper participation in current screening procedures such as colonoscopy. These barriers include bowel cleansing requirements, risks associated with anesthesia and patient concerns over potential pain,&#8221; said Prof. Nadir Arber, M.D., Director, Integrated Cancer Prevention Center at the Israel Tel Aviv Sourasky Medical Center, president of the Israeli Gastroenterological Society and scientific advisor to Check-Cap. &#8220;These data validate the potential of a less invasive, patient-friendly modality that can screen the colon&#8217;s interior and provide 3D imaging of the colonic wall without the need for bowel preparation.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Preliminary analysis of the ongoing clinical feasibility study evaluated data from participants who swallowed Check-Cap's scanning capsule, tracking the entire passage of the capsule through the alimentary tract using radio frequency telemetry and Check-Cap's proprietary capsule position tracking system. Pedunculated and sessile polyps were clearly seen and validated by subsequent colonoscopy, and the total radiation exposure was found to be ultra-low (0.03&#177;0.007 mSv, or the equivalent exposure of one chest x-ray). Capsules were excreted naturally in all 48 volunteers who completed the study (one asymptomatic volunteer withdrew prior to completion and the capsule was retrieved endoscopically from the colon). Initial data show the system to be safe, as well as able to produce 3D reconstructions of the colonic wall and lumen, including identifying polyps.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#8220;We are pleased to see the publication of these studies in a prestigious, peer-reviewed international medical journal,&#8221; said Bill Densel, CEO of Check-Cap &#8220;These data showed safe passage, very low radiation exposure and&#160;&#160;the ability of the system to reconstruct the human colon and to enable polyp identification without the need for bowel preparation. We continue the evaluation of our system, and we believe that a less-invasive, preparation-free modality addresses significant barriers and has the potential to increase adherence to colorectal cancer screening recommendations.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The publication is currently available online at http://gut.bmj.com/ and will also be featured in an upcoming print edition of <font style="FONT-STYLE: italic; DISPLAY: inline">Gut</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Check-Cap</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check-Cap is a clinical stage medical diagnostics company developing the first system for preparation-free scanning and imaging of the inner colon to identify precancerous polyps and cancers while being less invasive than traditional procedures. The Company is developing an ingestible capsule that utilizes proprietary, ultra-low-dose X-ray technology to safely generate high-resolution, 3-dimensional imagery of the interior of the colon. Without requiring bowel preparation or diet and activity modifications, Check-Cap's system is designed to increase patient acceptance and adherence to colorectal cancer screening recommendations. The Check-Cap system is currently not cleared for marketing in any jurisdiction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Notice Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains &#8220;forward-looking statements.&#8221; Words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions, as well as statements in future tense, often signify forward-looking statements.&#160;&#160;Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.&#160;&#160;Forward-looking statements are based on information that the Company has when those statements are made or management&#8217;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.&#160;&#160;For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the &#8220;Special Note On Forward-looking Statements&#8221; and &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC&#8217;s web site at http://www.sec.gov.&#160;&#160;The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTACT:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Investors</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Carey</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lazar Partners Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212-867-1768</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">dcarey@lazarpartners.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vivian Cervantes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PCG Advisory Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212-554-5482</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">vivian@pcgadvisory.com</font></div>
</td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Media</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Danielle Lewis or Erich Sandoval</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lazar Partners Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212-843-0211 or 917-497-2867</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">dlewis@lazarpartners.com </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">esandoval@lazarpartners.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $P
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M\0]PO_/V7W(/]:*W\B_$_KE_X?)?LL_]%Y^''_@T2C_A\G^RP/\ FO/PX_\
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MM(^"?"OP]^-OB+2O!'B6U\6^$8+IFTC4X ZB:W;YD5@P!#J#M;CJN>]>G?\
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MQ'K#)MDSZ!AWKYGBK)ECL&W!>_#5?JOG^=CV,EQ_U>ND_AEH_P#,_;#]@_\
MX)-P?L5?\%B/C#X_T734@\ ^*/#*7/AW:F(["XN[L-=VJ^FQH<J/[DJCM7U;
M^T[J9EU[3+(-E8(&E(]V;'\EKV6VE2XA22-EDCD 974Y5@1D$'N*\"_:#NC<
M?$F=.T,,:#\L_P!:_%L;C:N*FJE9W:27W*Q][AZ$*47&&S;?WGYM_P#!8_\
M8E\??%G6/ OQD^$4<EU\0_AE+N%E#@SW< D\U&B!X=XWW93^)7(&2,'A?@5_
MP5A_:8^-GQ/\(^$'_9\N=$EGU2VM_$&KR:;>B*WMO,43R!)%5(SLW')9L=LU
M^D]/>>21=K.[+Z%B17H4<ZBL-'#XBC&IRWY6[IJ_IOKJKG-4P#]JZM*;C?==
MS\C?@CKWQ5_8$_;V^.,-W\#O%?Q/\2?$B^F;P_K5E$PCV/-*\;&Y92JPNLB;
M_F!7R@#P*YW_ ()\GXE?![]F+]I+X>^)/A=XDT2RO=)U?5M3UR^B>WMK*5+1
MHTMHPP D9VW'<I(VC/?-?LF)G5"@=@IZC/!KA?VG_ >J?%S]G'QUX6TDPR:K
MX@T*[TZS6>7RXO-EA9%#-_",D9/:O1AQ+&I^[G22YN1-W?V;6=ME;L<TLJ<?
M>C-Z<UE9==T?D;_P3V_X*(_'/]GW]CO3? _P^^!6I^,8KFXNFT7Q%#;W,T E
MDD._<B(4<H_8NHXYK[=_X([_ +"GBO\ 9:\#^+/&GQ*<-\2?B;>B^U*$N)'L
M8@S.(W8<>8SR.[ <#Y1V->B?\$JOV9_%O['O[&>B>!/&2V$.NV%[=W$R6%W]
MH@V2REDPX R<>U?4'@WP3?>.M76TLHSC@RRD?)"OJ?\ #O49YG<*DZU#"P45
M.6LE=N23NO1==!Y?@)1C3J5I-N*T3Z'4?L^>#FU[Q<-1D3-KIGS GHTA'RC\
M.OY5[S67X/\ "=KX+T&&PM%.R+EF/WI&/5C[FM2OETCV H(!ZBBBF!\[_MY?
M\$N?@Y_P48\+QV?Q&\-)-JUI&8[#7M/86VJV ]$F .Y<\['#+[5^1O[1G_!H
M?\1?#>I7$_PL^)7AOQ/II.8;37X'TZ]4?W3)&'C;ZX7/H*_?JBO:RWB''X%<
MM"I[O9ZK\=OD>?BLKP^(=ZD=>ZW/YCYO^#7K]KF.5E7PWX+E"G 9?$T #>_(
M!I1_P:[?M<$ GP]X)!/_ %,T/^%?TWTFP>E>U_KYF?:/W/\ S.'_ %<PGG]_
M_ /YDO\ B%U_:X_Z%[P3_P"%+#_A1_Q"Z_M<?]"]X)_\*6'_  K^FW8/2C8/
M2A<>9GVC]S_S#_5S">?W_P# /YDO^(77]KC_ *%[P3_X4L/^%'_$+K^UQ_T+
MW@G_ ,*6'_"OZ;=@]*-@]*7^OF9]H_<_\P_U<PGG]_\ P#^9+_B%U_:X_P"A
M>\$_^%+#_A2'_@UU_:W.0?#_ ()P?^IFA_PK^F[8/2E"@<@4?Z]YGVC]S_S!
M<.83S^__ (!XQ_P3S\+?$;P%^QG\/O#WQ9M[.W\?>'=*32]3-K>+=Q3^03'%
M*)!U+Q*C'T8FIOB?\&]>\5^-[V_M(K9K:;;L+3!2<*!TKV&BOD*U3VDW-JUW
M?3;4]R$.6*BNA\__ /#//B;_ )X6?_@0*/\ AGGQ-_SPL_\ P(%?0%%9<J*/
MG_\ X9Y\3?\ /"S_ / @4L?[._B5V :*R0'N;@$#\A7O]%'*@/)/#/[,8219
M-7U .HY,-L, ^Q8_T%>G:#X>LO#.GI:V%M';0)_"HZGU)[GW-7:*$@"BBBF!
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
